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PURPOSE. To determine whether ROCK inhibition for the treatment of glaucoma can be
improved by using novel, locally acting Rho kinase (ROCK) inhibitors, such as AMA0076, that
lower IOP without inducing hyperemia.
METHODS. On-target potency of AMA0076 was compared with other ROCK inhibitors (Y-27632
and Y-39983) and conversion of AMA0076 into its functionally inactive metabolite was
evaluated in rabbit eye tissues. Human trabecular meshwork (HTM) cell morphology, actin
filaments, and focal adhesion were studied in vitro after exposure to AMA0076. The effect of
AMA0076 on IOP was investigated in normotensive rabbits and a new, acute hypertensive
rabbit model. Intraocular pressure lowering efficacy of AMA0076 was compared with
pharmacologic treatments. Hyperemia after single topical dosing of AMA0076 and Y-39983
was scored.
RESULTS. AMA0076 and Y-39983 showed similar on-target potency. AMA0076 was most stable
in aqueous humor and converted into its metabolite in other eye tissues. Exposure of HTM
cells to AMA0076 led to significant and reversible changes in cell shape and a decrease in
actin stress fibers and focal adhesions. Both AMA0076 and Y-39983 provided an equivalent
IOP control. Compared with latanoprost and bimatoprost, AMA0076 was more potent in
preventing the IOP elevation in the acute hypertensive rabbit model. The degree of
hyperemia was significantly lower in rabbits treated with AMA0076 then with Y-39983.
CONCLUSIONS. AMA0076 is a locally acting ROCK inhibitor that is able to induce altered cellular
behavior of HTM cells. Administration of AMA0076 effectively reduces IOP in ocular
normotensive and acute hypertensive rabbits without causing distinct hyperemia.
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The most common form of glaucoma is POAG, which affectsmore than 2 million persons over 40 years of age in the
United States (USA) alone.1 Elevated IOP is the only proven,
treatable risk factor in multiple forms of glaucoma including
POAG.2,3 Pharmacologic lowering of IOP has been demonstrat-
ed to decrease the risk of progression to POAG in patients with
ocular hypertension (OH) and to decrease disease progression
in patients with both early and advanced POAG, as well as in
those with normal-tension glaucoma.4–9
Intraocular pressure is determined by the balance between
aqueous humor (AH) production and outflow from the eye.
Outflow occurs via two pathways: the trabecular (convention-
al) and uveoscleral (unconventional) pathways. The main route
of outflow is via the conventional pathway.10 The primary
disease mechanism in POAG involves increased trabecular
resistance to AH outflow via this pathway,11,12 resulting in
elevated IOP.13 Therefore, agents that increase AH outflow by
lowering the trabecular resistance are promising for the
treatment of POAG and OH.14 Multiple treatment options for
IOP control are available, including topically applied and oral
drugs, laser treatments, and surgery.15 First line topical
treatment usually occurs with prostaglandin analogues (PGAs)
or beta-blockers, while second line treatment, includes
carbonic anhydrase inhibitors, alpha-2 selective antagonists,
and cholinergic agents.16 Since the declining use of cholinergic
agents, such as pilocarpine, it is noteworthy that none of the
routinely used medications significantly improves conventional
outflow.17 As such, a drug that targets this pathway could
potentially lead to advancement in the care of OH and POAG
patients.18–20 Further, because the conventional pathway is
pressure-sensitive18 (unlike the unconventional pathway), a
drug-targeting conventional outflow may allow for better/
quicker IOP spike recovery compared with drugs that target
either AH production or uveoscleral outflow.21
Rho kinase inhibitors constitute a new pharmacologic class
of potential drugs that decrease IOP22–25 via effects on the
Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
www.iovs.org j ISSN: 1552-5783 1006
trabecular meshwork (TM) and as such increase conventional
outflow facility.26 Preclinical data indicate that ROCK
inhibitors such as Y-27632 (trans-4-[(1R)-1-aminoethyl]-N-4-
pyridinylcyclohexanecarboxamide dihydrochloride), Y-39983
(4-[(1R)-1-aminoethyl]-N-1H-pyrrolo[2,3-b]pyridin-4-ylbenza-
mide hydrochloride), and Fasudil (1-(5-isoquinolinylsulfonyl)-
homopiperazine dihydrochloride) alter the contractility of the
TM cells, thereby lowering IOP by facilitating conventional
outflow via the relaxation of cells in the TM.22–25,27 However,
preclinical and clinical studies evaluating ROCK inhibitors
have reported mild to severe conjunctival hyperemia, which
is most likely due to mechanism-based smooth muscle cell
relaxation in conjunctival blood vessels.25,28 As a result, most
ROCK inhibitors display a narrow therapeutic window.
Therefore, Amakem Ophthalmics (Diepenbeek, Belgium)
developed a product pipeline of soft ROCK inhibitors. In
general, soft drugs, also known as antedrugs or locally acting
drugs, are biologically active compounds that are designed to
undergo metabolic inactivation by controlled conversion of
the parent molecule into a predictable, nontoxic metabo-
lite.29 AMA0076 is a novel, potent ROCK inhibitor resulting
from Amakem Ophthalmics efforts toward the development
of 3-[2-(aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] ben-
zoates as soft ROCK inhibitors. These compounds contain
carboxylic ester moieties, which allow inactivation by
esterases and could potentially display an increased thera-
peutic window.30
The goal of the present study was to elucidate the IOP-
lowering potency and in vivo safety profile of AMA0076. In
vitro experiments were performed to investigate the on-target
potency and stability of AMA0076, as well as the effect of the
ROCK inhibitor on the cytoskeleton and morphology of
cultured human TM cells. The IOP-lowering effect was
investigated using ocular normotensive rabbits and an acute
hypertensive rabbit model. The in vivo effect was compared
with Y-39983 and two PGAs, latanoprost and bimatoprost,
which are routinely used in the clinic as IOP-lowering agents.
Moreover hyperemia was scored after single topical adminis-
tration and compared with the known ROCK inhibitor, Y-
39983.
MATERIALS AND METHODS
In Vitro On-Target Activity Measurements
The on-target activity of AMA0076 was determined and
compared with Y-39983 and Y-27632, using a radiometric
protein kinase assay (1 lM ATP).31 The kinetics of ROCKII
inhibition by AMA0076 were characterized by varying the
concentrations of ROCKII (aa5-554), peptide substrate (long S6
kinase substrate peptide) and ATP, and measuring inhibition at
different time points (up to 120 minutes). Data were analyzed
with Michaelis-Menten and Lineweaver-Burk plots.
Animals
Male New Zealand White (NZW) rabbits (animal facility, KU
Leuven, Leuven, Belgium) aged 12 to 14 weeks and weighing 2
to 3 kg, were used in all studies. All experiments were
conducted in accordance with the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research and were
approved by the ethical committee for the use of animals at KU
Leuven.
Stability in Eye Tissues
Eye tissues (cornea, conjunctiva, sclera, and AH) were
collected from (NZW) rabbits (animal facility, KU Leuven),
snap frozen and stored at 808C. On the day of the
experiments, tissues were divided into equal pieces and
weighted. Next, all samples were immersed into freshly
prepared glutathione bicarbonate Ringer’s (GBR) buffer
oxygenated with O2/CO2 (95:5) to pH 7.4, and were spiked
with AMA0076 to a final concentration of 20 lM. After 4-hours
incubation at 378C samples were taken at fixed time points and
put into ice-cold ACN/H2O (Merck, Darmstadt, Germany)
containing the internal standard warfarin (Fluka; Sigma-Aldrich,
Steinheim, Germany), for protein precipitation. The remnant
of compound was determined by liquid chromatography-
tandem mass spectrometry (LC/MS-MS) using Analyst Software
(AB Sciex, Niewerkerk aan den Ijssel, The Netherlands). The
LC/MS-MS apparatus consists of two parts: the LC part
(LC20AD; Shimadzu, Duisburg, Germany) and the MS-MS
connected to the LC part (3200 Q TRAP LC/MS/MS system;
AB Sciex, Applied Biosystems, Niewerkerk aan den Ijssel, The
Netherlands). A calibration curve of AMA0076 was made in
GBR buffer to calculate the remaining concentration. Based on
the data and the weights of the tissues of at least three
independent experiments, the rate of metabolism was calcu-
lated, assuming first order decay, and specific enzymatic
activity was presented as picomole per minute per milligram
6 SEM.
Culture of Human Trabecular Meshwork (HTM)
Cells
Human TM cells were obtained from ScienCell Research
Laboratories (Carlsbad, CA) and cultured in poly-L-lysine
coated T75 flasks (ScienCell Research Laboratories). Cells
were maintained at 378C in a humidified atmosphere of 5%
CO2. Medium was replaced every 2 days and once confluent,
cells were passaged in a one-fourth ratio using the trypsin-
EDTA method. Briefly, cells were incubated with 0.25% trypsin-
EDTA (Gibco, Carlsbad, CA) for 5 minutes at 378C and 5% CO2.
Afterwards, cells were centrifuged for 5 minutes at 312 g and
plated. Cells between the third and sixth passage were used in
all experiments.
Effect on Human TM Cell Morphology
Confluent cultures of human TM cells were incubated with
AMA0076 1 lM or dimethyl sulfoxide (DMSO) at similar
concentration as vehicle. Cultures were observed with an
inverted microscope (Primo Vert Zeiss, Oberkochen, Germany)
and photographed before application and 60 minutes after
administration of AMA0076. The solution was replaced with
full medium and incubated again for 15 hours to examine
whether the effects of AMA0076 on human TM cells were
reversible.
Actin and Vinculin Staining
Human TM cells were plated on cover glasses in a 12-well plate
at a density of 203103 cells per well. When cells reached semi
confluence, 1 lM of AMA0076 was added and DMSO was used
as vehicle. One hour after drug exposure, cells were fixed with
1% paraformaldehyde (PFA) for 20 minutes at room tempera-
ture (RT). F-actin and focal adhesions were stained using the
FAK 100 actin cytoskeleton/focal adhesion staining kit (Milli-
pore, Billerica, MA) according to the following protocol.
Briefly, cells were permeabilized using 0.1% Triton X-100 in
PBS for 5 minutes at RT and rinsed with PBS. Blocking solution
(1% bovine serum albumin; Roche Diagnostics GmbH, Mann-
heim, Germany) was applied for 30 minutes. The cells were
incubated with antivinculin (focal adhesions; 1:300 in blocking
solution) at RT for 1 hour and rinsed with PBS. Next, cells were
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incubated at RT for 1 hour with AlexaFluor 488-conjugated
goat anti-mouse (1:200) and tetramethylrhodamine-5-(and-6)-
isothiocyanate (TRITC)-phalloidin (F-actin, 1:100), both diluted
in PBS. Cells were washed and mounted with Prolong Gold
antifade reagent with 40, 6-diaminido-2-phenylindole (DAPI;
Invitrogen, Carlsbad, CA). Fluorescence was visualized with a
confocal laser scanning microscope (FV 1000; Olympus,
Melville, NY). To determine whether the effects of AMA0076
on human TM cells were reversible, the drug solution was
replaced with full medium and followed by incubation for
another 15 hours.
IOP Measurements
An applanation tonometer (Tono-Pen; Medtronic Solan, Jack-
sonville, FL) was used to monitor IOP and three recordings per
eye were averaged. Before the start of each IOP experiment the
OCU-FILM tip cover was renewed and the tonometer was
calibrated. The rabbit eyes were anesthetized by topical
instillation of 0.4% oxybuprocaine (Unicaine; The´a Pharma,
Schaffhausen, Switzerland) before every IOP measurement.
Ocular Normotensive NZW Rabbits
In a first set of experiments the IOP-lowering efficacy of single
topical administration of AMA0076 at concentrations of 0.1%,
0.3%, and 0.5% was tested in ocular normotensive NZW
rabbits. These results were compared with Y-39983 (0.1%,
0.3%, and 0.5%) and to the PGA latanoprost (Xalatan 0.005%;
Pfizer, New York, NY). The contralateral eyes of the
AMA0076/Y-39983-treated rabbits received vehicle (H2O/
polyethylene glycol [PEG]). Intraocular pressure measure-
ments were performed immediately before and every hour
until 8 hours after single administration of the compounds.
Latanoprost was administered at two different time points in
two separate experiments. In the first experiment, latano-
prost was administered the evening before IOP measure-
ments. In a second experimental set-up, we also tested the
effect of latanoprost when dosed in the morning on the day of
IOP measurements (as AMA0076 and Y-39983). In both
experiments contralateral eyes were treated with saline
(0.9% NaCl; B. Braun Medical, Bethlehem, PA). In the above
experiments all IOP measurements were performed between
8 AM and 5 PM.
Furthermore, the effect of AMA0076 0.3% and latanoprost
on IOP was investigated during the night. Compounds were
instilled at 8 PM and IOP was measured every 2 hours until 10
hours after administration with a final measurement at 18
hours after instillation. Contralateral eyes of AMA0076 treated
animals received vehicle (H2O/PEG) and saline was adminis-
tered to the contralateral eyes of rabbits treated with
latanoprost.
Ocular Hypertensive Rabbit Model
Before inducing hypertension, IOP was measured in both eyes.
Subsequently, rabbits were anesthetized by an intramuscular
injection of 50 mg/mL ketamine (Ketalar; Pfizer, Ann Arbor, MI)
and 2% Rompun (Bayer Health Care, Pittsburgh, PA). Ocular
hypertension was induced by injection of 50 lL Viscoat (Alcon
Laboratories, Fort Worth, TX) with a blunt ophthalmologic
needle (Steriseal ophthalmologic cannula, 27 G); Aspen
Medical Europe Ltd., Reddittch, The Netherlands) into the
anterior chamber (AC). Before injection, a temporal paracen-
tesis was created with a sharp 26-G needle (Terumo Europe
N.V., Leuven, Belgium). After injection, the paracentesis was
hydrated with saline to prevent reflux of AH.
Compound Testing in Ocular Hypertensive Model
In a first experiment, rabbits were divided in different groups, in
which the IOP-lowering effect of commercially available IOP-
lowering drugs, latanoprost and timolol (Timolol 0.5%; Falcon,
Fort Worth, TX) and AMA0076 (0.1%, 0.3%, and 0.5%) was
tested. All compounds were administered topically three times
at 0 (9 AM), 3 (12 AM) and 6 (3 PM) hours after Viscoat
injection. Saline was administered to the contralateral eye of
rabbits treated with latanoprost and timolol, whereas vehicle
(H2O/PEG) was used as control in the AMA0076 treated rabbits.
In a second experiment, a head to head comparison
between AMA0076 and the PGAs, latanoprost and bimatoprost
(Lumigan 0.3 mg/mL; Allergan, Westport, Ireland) was
performed. AMA0076 was instilled three times at the day of
the experiment. Prostaglandin analogues were administered
the evening before induction of hypertension, to have their
maximal effect at the time of the IOP elevation challenge.
Intraocular pressure was measured immediately before
injection of Viscoat and every hour until 8 hours after inducing
OH.
Hyperemia Scoring
New Zealand White rabbits were used to investigate the
hyperemic effect after single dosing of AMA0076, Y-39983, and
vehicle. Eyes were photographed using a digital camera (EOS 5D
Mark II [100-mm lens]; Canon, Inc., Tokyo, Japan) before, 1, 4,
and 8 hours after topical instillation of the compounds.
Hyperemia was scored using a scoring system developed by
Alcon Research, in which a number is given to the area of
vasodilatation: 0 was normal appearance of vessels at limbus and
on rectus muscle; 1 was enlargement of vessels normally visible
at limbus and on rectus muscle; 2 was branching of vessels at
limbus, new vessels are visible; 3 was new vessels visible in
open bulbar conjunctival areas; and 4 was diffuse redness in
open bulbar conjunctival areas. The numbers 0 and 1 indicate
normal scores; 2, 3, and 4 represent adverse events.32
Statistical Analysis
Data at individual time points were analyzed using the
Student’s t-test for independent samples. The time course of
IOP changes was analyzed using ANOVA for repeated
measurements (GraphPad Prism 5.0; GraphPad Software, Inc.,
San Diego, CA). P values smaller than 0.05 were considered
statistically significant. Data were presented as mean 6 SEM.
RESULTS
AMA0076 is a Potent, Reversible, and ATP-
Competitive ROCK Inhibitor
Since AMA0076 is a novel ROCK inhibitor, we first
determined its on-target potency and compared it with
other known ROCK inhibitors (Y-39983 and Y-27632).
Analysis showed that AMA0076 is a potent inhibitor of
ROCKI and ROCKII with similar potencies on both isoforms
(Table 1). AMA0076 was equipotent to Y-39983 and
approximately 30-fold more potent than Y-27632 (Table 1).
As AMA0076 and Y-39983 showed similar on target potency
for ROCKII, we used Y-39983 as a reference ROCK inhibitor
for all in vivo studies.
Inhibition of ROCKII by AMA0076 was competitive with
respect to ATP and noncompetitive compared with long S6
kinase peptide substrate (Table 2). Inhibition was time-
independent and decreased by dilution of the reaction
mixture, suggesting reversible binding (data not shown).
IOP Lowering of AMA0076 in NZW Rabbits IOVS j February 2014 j Vol. 55 j No. 2 j 1008
AMA0076 Is Stable in Aqueous Humor and
Metabolized in Rabbit Eye Tissues
AMA0076 differs from other ROCK inhibitors by its soft drug
properties. The conversion of AMA0076 into its functionally
inactive metabolite was evaluated in NZW rabbit eye tissues
(cornea, conjunctiva, and sclera) and AH. The observed
degradation rates were converted into specific activities for
each tissue, in order to provide a suitable comparison (Table
3). Low specific activity (0.13 pmol min1 mg1) was found in
the collected AH samples. Higher specific activities were found
in all tested tissues. Cornea displayed the highest specific
activity, followed by conjunctiva and sclera (4.81, 1.93, and
1.25 pmol min1 mg1, respectively). Overall, these values
suggest that significant conversion of AMA0076 occurs in vivo
in all three tissues, confirming its soft drug properties.
AMA0076 Induces Morphologic and Cytoskeleton
Changes in HTM Cells
Next, the effect of AMA0076 on TM cells was tested in vitro. It
has been previously shown that ROCK inhibitors (Y-27632, Y-
39983, and HA1077) induce morphologic changes in TM
cells.22–24,33 Therefore, we exposed semiconfluent cultures of
human TM cells to AMA0076. Treatment with AMA0076
induced cell–cell separation (retraction) and thinning of the
cells after 60 minutes. Replacement of drug solution with full
medium resulted in recovery of normal cell morphology (Fig.
1A). To examine whether these morphologic changes were
due to cytoskeletal rearrangements, the effect of AMA0076 on
the cytoskeleton was investigated by immunofluorescent
staining. In control cells, actin filaments assembled into large
radial bundles associated with focal adhesions (Fig. 1B, left
panel). Exposure to AMA0076 induced distinct alterations in
the actin filament organization and focal adhesions of human
TM cells (Fig. 1B, middle panel). After treatment with
AMA0076, cells lost most of their actin bundles and residual
actin filaments became associated with the cell periphery
rather than with focal adhesions. Exposure to AMA0076
caused a significant decrease in vinculin expression at the
focal adhesion points. All these cytoskeletal changes returned
to normal after compound replacement with full medium
(Fig. 1B, right panel). There was no effect of the vehicle on
general morphology or actin/vinculin staining of HTM cells
(data not shown).
Taken together, these data indicate that ROCK inhibition by
AMA0076 modifies TM cell morphology.
Single Administration of AMA0076 Effectively
Lowers IOP in Normotensive NZW Rabbits
We then used an in vivo animal model to test the IOP-lowering
efficacy of AMA0076. In normotensive NZW rabbits, a single
topical administration of the compound significantly decreased
IOP compared with control eyes in a dose-dependent manner
(Figs. 2A–C). The IOP reduction was significant already 1 hour
post dosing, and was sustained for 6 to 8 hours, after which
IOP returned to baseline. The peak IOP-lowering efficacy was
observed 2 hours post dosing for the 0.5% and 0.3%
concentrations, and 4 hours post dosing for the 0.1%
concentration. Maximum IOP reduction compared with
baseline values after a single dose of AMA0076 at a
concentration of 0.5%, 0.3%, and 0.1% was 48% 6 0.32 (P ¼
0.03), 39% 6 0.41 (P ¼ 0.003), and 23% 6 0.17 (P¼ 0.0006),
respectively (Fig. 2D). A single administration of Y-39983 also
significantly lowered IOP compared with vehicle-treated eyes
(Figs. 2E–G). Maximum IOP reduction was reached 2 hours
after instillation with Y-39983 at 0.5%, 0.3%, and 0.1% (Fig. 2H).
Compared with baseline values, IOP was reduced by 38% 6
0.55 (P ¼ 0.01), 34% 6 0.34 (P ¼ 0.01), and 27% 6 0.57 (P ¼
0.07), respectively. Noteworthy, an attenuated IOP-lowering
effect was also observed in the contralateral eye of animals
treated with Y-39983. This contralateral effect was not
observed in the AMA0076 treated animals. Since this might
lead to an underestimation of the IOP reduction by Y-39983,
the maximum IOP-lowering effect in all experiments was
expressed as compared with baseline.
Finally, we compared the IOP-lowering efficacy of AMA0076
to latanoprost. We tested the effect of latanoprost on IOP after
two different time points of administration. First, latanoprost
was administered the evening before IOP measurements
because, as in humans, latanoprost acts as a prodrug when
administered topically to the rabbit eye. Indeed, the cornea
serves as a slow release depot and supplies the active form of
latanoprost to the anterior segment during an extended period
of time.34 Next, we also tested the effect of latanoprost when
dosed the day of the IOP measurements. In both experiments,
administration of latanoprost to ocular normotensive NZW
rabbits did not reduce the IOP measured during the day (Figs.
3A, 3B). Compared with contralateral eyes, AMA0076 and
latanoprost were able to significantly reduce IOP measured at
night, with the peak IOP-lowering effect of both agents being
25.25% and 22.16%, respectively (Figs. 3C, 3D). In conclusion,
the efficacy of AMA0076 was comparable with latanoprost
when IOP measurements were performed at night. However,
in contrast to latanoprost, AMA0076 reduced IOP also during
the day with a potency equal to Y-39983.
TABLE 1. Relative Potencies (IC50 Values, nM) for ROCK I and II
Inhibition by AMA0076 and Reference Compounds
Compound ROCK I ROCK II
AMA0076 3.7 6 2.0* 2.3 6 0.9*
Y-27632 ND 54 6 23†
Y-39983 ND 4.3 6 2.1*
ND, not determined.
* Average of three independent experiments.
† Average of two independent experiments.
TABLE 2. Kinetic Parameters of In Vitro ROCKII Inhibition by
AMA0076
Coincubation
ATP Peptide Substrate
Mode of inhibition Competitive Not competitive
Km 14 lm <0.1 lm
Ki 9.4 nM ND
TABLE 3. Specific Activities (pmol min1 mg1) of NZW Rabbit Eye
Tissues and Aqueous Humor for Conversion of AMA0076
Tissue Specific Activity 6 SEM
Cornea 4.81 6 1.21
Conjunctiva 1.93 6 0.20
Sclera 1.25 6 0.31
Aqueous humor* 0.14 6 0.01
* 1 lL AH was approximated to 1 mg.
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AMA0076 Is More Potent Than Prostaglandin
Analogues in an Acute Hypertensive Rabbit Model
To further test the efficacy of AMA0076 against PGAs we set
up a hypertensive rabbit model. A single intracameral
injection of viscoelastic material (Viscoat) in NZW rabbit
eyes resulted in a rapid IOP increase reaching peak pressures
of 30 mm Hg approximately 5 hours after injection (Fig. 4A).
Twenty-four hours after injection of Viscoat, IOP consistently
returned to pre-injection levels. Injection of saline did not
influence IOP.
In a first experiment, the IOP-lowering agents, latanoprost
and timolol, were evaluated in the hypertensive rabbit model.
Latanoprost significantly prevented IOP rise after injection
with Viscoat compared with saline-treated eyes (Fig. 4B),
whereas timolol did not lead to pronounced IOP lowering in
this model (Fig. 4C). These data confirm that this hypertensive
model is suitable to evaluate compounds that directly target
outflow, rather than compounds that decrease AH production.
Topical administration of AMA0076 significantly and dose-
dependently prevented the IOP rise compared with vehicle-
FIGURE 1. (A) Effect of AMA0076 on morphology of cultured HTM cells. Treatment of HTM cells with 1 lm of AMA0076 for 60 minutes resulted in
retraction and thinning of the cells. Recovery of normal morphology was observed 15 hours after replacement of drug solutions by full medium. (B)
AMA0076 induces changes in actin fibers and focal adhesion (FA) in human TM cells (left panel). Normal distribution of actin fibers (red) and
vinculin (green) in human TM cells (middle panel). Distribution of actin and vinculin in human TM cells treated with 1 lM AMA0076 for 60 minutes
(right panel). Drug solution was removed after and replaced by full medium. Recovery of normal morphology was observed 15 hours later.
IOP Lowering of AMA0076 in NZW Rabbits IOVS j February 2014 j Vol. 55 j No. 2 j 1010
treated eyes (Fig. 4D). AMA0076 0.1% attenuated the IOP rise
induced by the injection of Viscoat compared with the control
eye (overall P < 0.0001; ANOVA), whereas topical administra-
tion of AMA0076 0.3% and 0.5% completely inhibited IOP
increase (overall P < 0.0001; ANOVA). Finally, a comparison
between AMA0076, latanoprost, and bimatoprost revealed that
AMA0076 was significantly more potent in preventing the IOP
elevation in this ocular hypertensive model (overall P <
0.0001; ANOVA; Fig. 5).
Overall, these data show that AMA0076 effectively lowered
IOP in an acute hypertensive rabbit model and was more
potent than PGAs.
FIGURE 2. Effect of single topical administration of AMA0076 and Y-39983 on IOP in normotensive NZW rabbits during the day. Contralateral eyes
were treated with vehicle (n¼ 5). (A–C) Time course of IOP reduction after topical administration of AMA0076 (0.1%, 0.3%, and 0.5%) or vehicle.
(*P < 0.05, **P < 0.01, and ***P < 0.001 compared with the vehicle group at each time point). (D) Maximum IOP reduction (%) after topical
administration of AMA0076 compared with baseline IOP before administration. (E–G) Time course of IOP reduction after topical administration of
Y-39983 or vehicle. (*P < 0.05, **P < 0.01, and ***P < 0.001 compared with the vehicle group at each time point). (H) Maximum IOP reduction (%)
after topical administration of Y-39983 compared with baseline IOP before administration. Intraocular pressure measurements were performed
between 8 AM and 5 PM.
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Minimal Conjunctival Hyperemia With AMA0076
ROCK inhibitors are known to induce mild to severe transient
conjunctival hyperemia.26 Therefore the hyperemic effect of
AMA0076 0.3% and Y-39983 0.3% was investigated in ocular
normotensive NZW rabbits. While vehicle-treated eyes did not
show distinguishable hyperemic effects, single administration
of Y-39983 induced significant hyperemia in the NZW rabbits.
In contrast, AMA0076 treatment only caused very mild
hyperemia. Table 4 and Figure 6 represent the degree of
hyperemia after single topical administration of AMA0076, Y-
39983, and vehicle before, 1, 4, and 8 hours after dosing. Thus,
compared with Y-39983, AMA0076 induced minimal conjunc-
tival hyperemia in NZW rabbits.
DISCUSSION
Our results demonstrate that AMA0076, a novel, locally acting
ROCK inhibitor significantly reduced IOP after topical admin-
istration. In contrast to other ROCK inhibitors, AMA0076 did
not cause significant hyperemia at a dose that resulted in
strong IOP reduction.
Exposure of human TM cells to AMA0076 led to a decrease
in actin bundles and focal adhesions, and thereby induced
changes in cell morphology. This finding is in line with the
reported effects of other ROCK inhibitors Y-27632, Y-39983,
and HA1077.22–24,33 Overall, ROCK inhibitors induce cytoskel-
etal rearrangements and loss of cell–extracellular matrix
interactions in TM cells. These modifications might lead to
increased intertrabecular pores in vivo and consequently
decrease resistance of AH outflow through the TM, leading
to a reduced IOP.
Compared with Y-39983, AMA0076 showed similar on
target potencies on ROCKII. The IOP-lowering effect of both
ROCK inhibitors was comparable at the tested doses. However,
after instillation of Y-39983, an attenuated IOP-lowering effect
was also observed in the contralateral vehicle-treated eye. This
finding was not observed with AMA0076 and might be
explained due to its soft properties. While the efficacy of
ROCK inhibitors is promising, they are associated with
significant hyperemia due to conjunctival vasodilatation.28 Soft
ROCK inhibitors like AMA0076 undergo rapid degradation
toward a predefined, functionally inactive metabolite.30 Such
compounds might reduce side effects and widen the thera-
peutic window of ROCK inhibitors.35 We therefore compared
the hyperemic effect of Y-39983, with AMA0076 that is
metabolized in rabbit eye tissues. Interestingly, the hyperemic
effect of a single topical ocular administration of AMA0076 in
NZW rabbits was very mild and significantly lower compared
with Y-39983 treatment. The mechanism(s) underlying this
phenomenon are yet to be fully elucidated. But it is possible
that AMA0076 remaining on the ocular surface is rapidly
FIGURE 3. Effect of latanoprost on IOP in ocular normotensive NZW rabbits (A) administered the evening before IOP measurements and (B) dosed
on the day of the IOP experiment (n¼5). Effect of single topical administration of AMA0076 (C) and latanoprost (D) on IOP in ocular normotensive
NZW rabbits during the night. Contralateral eyes were treated with vehicle in rabbits treated with AMA0076 or saline for latanoprost (n¼ 4). (*P <
0.05, **P < 0.01, and ***P < 0.001 compared with the vehicle/saline group at each time point).
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metabolized and therefore less likely to reach the conjunctival
blood vessels to cause hyperemia. However, once AMA0076
gets through the cornea, the remaining is more stable in AH.
The relevance of this observation is significant. Several ROCK
inhibitors have already been abandoned in clinical testing, and
hyperemia is often suggested to be one of the reasons.28
Prevention of hyperemia possibly led to suboptimal dosing
with those ROCK inhibitors, resulting in limited IOP lowering.
The highest dose of Y-39983 tested in phase 2 trials was 0.1%.36
Our results show that maximal IOP lowering is clearly not
reached at this dose in NZW rabbits. The ability to dose
sufficiently high without causing unacceptable levels of
hyperemia is considered to be critical for ROCK inhibitors to
be acceptable as IOP-lowering medication for the treatment of
glaucoma.28
As PGAs are an important treatment modality for glaucoma,
we compared the IOP-lowering effect of AMA0076 to PGAs. In
our study, latanoprost was unable to reduce IOP in ocular
normotensive NZW rabbits during the day. This finding is in
line with several previous reports37–39 but contradicts with
FIGURE 4. Intraocular pressure lowering effect in hypertensive rabbit model. (A) Effect of Viscoat injection on IOP in NZW rabbits. Control eyes
were injected with saline. Intraocular pressure lowering effect of (B) latanoprost and (C) timolol in hypertensive rabbit model. Latanoprost and
timolol was topically administered (arrows) to one eye, the contralateral eyes were treated with saline (n¼ 5). (D) Dose response of AMA0076 in
hypertensive rabbit model. AMA0076 was topically administered (arrows) to one eye, the contralateral eyes were treated with saline (n¼ 5; *P <
0.05, **P < 0.01, and ***P < 0.001, compared with the vehicle group at each time point). Intraocular pressure measurements were performed
between 8 AM and 5 PM.
FIGURE 5. Head to head comparison of AMA0076, latanoprost (A) and bimatoprost (B) in hypertensive rabbit model (n ¼ 5). AMA0076 was
administered three times (0, 3, and 6 hours after injection of Viscoat), latanoprost and bimatoprost were administered the evening before induction
of hypertension (*P < 0.05, **P < 0.01, and ***P < 0.001, compared with latanoprost or bimatoprost at each time point). Curve of saline treated eyes
(dotted line) was added to each graph as extra information. Intraocular pressure measurements were performed between 8 AM and 5 PM.
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others, which did show an IOP-lowering effect of latanoprost
in normotensive rabbits.40–42 The IOP-lowering effect of
latanoprost in rabbits still remains a matter of debate. The
reason for the difference may be attributed to variations in
method and timing of measurement as well as differences in
baseline IOP.40,42 This is also reflected by our data. We were
only able to reveal an IOP-lowering effect of latanoprost during
the night indicating that, in rabbits, the effect of latanoprost
depends on the time of day. Rabbits have a clear circadian
rhythm of IOP; low during the light phase and high during the
dark phase.43,44 Furthermore, the observed IOP-lowering effect
of latanoprost solely during the time of the day when IOP is
highest suggests that the effect on IOP of latanoprost may
depend more on baseline IOP than AMA0076. Since IOP
fluctuations are known to be a risk factor for glaucoma
progression, this finding may be relevant to clinical practice.45
In order to further compare the effect of AMA0076 on IOP
reduction to currently available glaucoma drugs, a hyperten-
sive rabbit model, based on the injection of viscoelastic agents
into the AC, was developed. Viscoelastic agents are commonly
used in ocular surgery to maintain AC depth. However, they
may cause IOP elevations in the immediate postoperatively
period.46 In rats the injection of viscoelastics has been used as
an OH model to test the IOP-lowering capacity of several
compounds.47 Therefore, we adapted the rat model to induce
OH in rabbits. Using this model, the capacity of compounds to
counteract the induced IOP elevation can be investigated.
Injection of Viscoat resulted in a rapid and consistent IOP
increase in NZW rabbits, most likely a consequence of
increased AH viscosity and disturbed outflow. Several available
IOP-lowering drugs, with different mechanisms of action were
evaluated in this model. Prostaglandin analogues, which
increase mainly uveoscleral AH outflow, successfully reduced
IOP, whereas timolol, which inhibits AH production, did not
have an effect. This finding confirms that only compounds
which target AH outflow are able to prevent the IOP rise in this
model. This is not unexpected, since AH suppressants
presumably further increase AH viscosity in this model, and
therefore have no IOP-lowering effect. Overall, our findings
show that the induced IOP elevation can be counteracted by
outflow facilitating drugs, and therefore this model can be used
to test the efficacy of compounds that act via this mechanism.
Gupta et al.40 also reported the IOP-lowering effect of different
IOP-lowering drugs in several hypertensive rabbit models. The
IOP-lowering effect of pilocarpine, timolol, and latanoprost
was investigated in a water-loading and steroid-induced OH
model. Latanoprost was found to be the most effective in both
models. Compared with our model the steroid-induced model
is more chronic; however, chronic administration of steroids is
associated with a high mortality rate, which was not the case
after Viscoat injection. In the water-loading model the IOP
increase is very acute and lasts only for 2 hours, whereas in our
model a consistent level of OH was induced for 4 hours.
Our study indicates that AMA0076 was more potent in
counteracting the IOP elevation compared with latanoprost
and bimatoprost in the hypertensive rabbit model. This might
be explained by the different mechanisms of action of the two
compound classes. Clinical and animal studies of AH dynamics
have reported that PGAs reduce IOP predominantly by
increasing uveoscleral outflow and to a lesser extent trabecular
outflow facility.48,49 Conventional outflow is considered the
main route and is believed to be regulated by the cellular
behavior and contractility of TM cells.50,51 Since ROCK
FIGURE 6. Hyperemic effect of AMA0076, Y-39983, and vehicle in NZW rabbits before, 1, 4, and 8 hours after dosing.
TABLE 4. Scoring of the Hyperemic Effect of AMA0076, Y-39983, and
Vehicle After Single Dosing
Before Dosing (0 h) 1 h 4 h 8 h
AMA0076 0.3% 0.20 0.60 0.20 0.35
Y-39983 0.3% 0.25 2.6 1.6 0.90
P value 0.69 0.00090 0.017 0.27
Vehicle 0.33 0.33 0.38 0.33
n¼ 5 NZW rabbits/compound. Overall P¼ 0.002 (AMA0076 versus
Y-39983).
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inhibitors are expected to have a stronger effect on the TM,
they have the potential to more effectively lower IOP.24,33
In summary, the present study shows that AMA0076 is a
potent ROCK inhibitor with a similar IOP-lowering efficacy as
Y-39983 and latanoprost, the latter only when dosed at night.
Compared with PGAs, AMA0076 was more potent in
preventing the IOP elevation in the acute hypertensive model.
Due to its soft drug behavior, AMA0076 clearly has an
improved tolerability profile with respect to hyperemia,
making optimal dosing possible. This increased tolerability
window makes AMA0076 a promising new candidate for the
treatment of glaucoma.
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